Most importantly, elevated Flot2 expression also showed shorter survival time in all patients (Figure 2D) as well as in subgroups of early (Stage I-III) (Figure 2E) and advanced (Stage IV) (Figure 2F) NPC. The gene discussed is FLOT2; the disease is nasopharyngeal carcinoma.